Openings in QC & QA Department at Hetero - B.Pharm, MSc, BSc Apply
B.Sc./B.Pharmacy/M.Sc. With Relevance Experience. HPLC,GC,IP/FP,RM, PM, Sampling, Wet Analysis, Stability, Microbiology
Hiring B.Pharm, BSc Freshers in Production & Packing at Hetero
Hetero is one of worlds leading producers of key Active Pharmaceutical Ingredients and generic formulations with presence in 140+ countries and backed by 30 years of experience in the pharma sector.
Regulatory Affairs Analyst require at Dr. Reddy’s Laboratories | M.Pharm Apply
You will be responsible for preparation, review and submission of Dossier in ANZ and Emerging Markets as per the applicable regulatory guidance in Emerging Markets. 
Hiring Multiple Position in Injection & Quality Control at Cadila Pharma
Ampoule Filling / Vial Filling / Autoclave / Sealing I Capping / Autocartonator / Bravity Visual Inspection. Pharmaceuticals Parenteral Manufacturing Experience Only
Interview for Sterile Injectables Experienced Professionals at Gland Pharma
To monitor the packing area in daily shifts in producing and delivering the committed daily plan volumes, safely, reliably, and with quality standards.
Akums Drugs Hiring for API R&D Unit
Good knowledge of HPLC / GC and wet lab instruments. Exposure of calibration of the instruments. Routine Analysis with GLP standards
Openings in Production, QC, QA Department at Beta Drugs Limited - M.Pharm, B.Pharm, MSc Apply
Beta Drugs Limited, part of the Adley Croup since 1985, is an Indian pharmaceutical company specializing in oncology.
Interview for Freshers at Aurobindo Pharma
Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India.
CDSA require PG in Pharma, Life Sciences as Program Officer | Salary Rs. 1,50,000 month
Postgraduate degree in Science / Pharmacology / Life Sciences / Regulatory Science/ Public Health from a recognised University with atleast 6 years of relevant work experience.
Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival
Merck known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 LITESPARK-022 trial in patients with clear cell renal cell carcinoma (RCC) following nephrectomy. In this study, KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with WELIREG